Cargando…
Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
Neoadjuvant chemotherapy is the current standard of care for large, advanced, and/or inoperable tumors, including triple‐negative breast cancer. Although the clinical benefits of neoadjuvant chemotherapy have been illustrated through numerous clinical trials, more than half of the patients do not ex...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476842/ https://www.ncbi.nlm.nih.gov/pubmed/32692484 http://dx.doi.org/10.1002/cam4.3284 |